Eris Lifesciences
Eris Lifesciences Share Price Chart
Eris Lifesciences last traded at ₹1,154.10 (2026-10-13). Over the past month the stock moved -14.8%, three months the stock moved -15.2%, year the stock moved -29.6%. Its closing range over 52 weeks is ₹1,150.40 – ₹1,666.00, with the latest close 30.7% below the high.
Closing prices up to 2026-10-13.
About Eris Lifesciences
ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.[1]
Market Position The company is a leading player in the domestic branded formulations market. It is the youngest among the top 20 companies in the Indian Pharmaceutical Market. [1]
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Eris Lifesciences reported sales of ₹873.00 crore (+12.9%) and net profit of ₹143.00 crore (+14.4%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 873.00 | 296.00 | 34.00 | 143.00 | 10.28 |
| Mar 2026 | 757.00 | 272.00 | 36.00 | 279.00 | 20.33 |
| Dec 2025 | 807.00 | 282.00 | 35.00 | 109.00 | 7.32 |
| Sep 2025 | 792.00 | 288.00 | 36.00 | 134.00 | 8.82 |
| Jun 2025 | 773.00 | 277.00 | 36.00 | 125.00 | 8.66 |
| Mar 2025 | 705.00 | 252.00 | 36.00 | 102.00 | 6.89 |
| Dec 2024 | 727.00 | 250.00 | 34.00 | 87.00 | 6.15 |
| Sep 2024 | 741.00 | 265.00 | 36.00 | 96.00 | 6.73 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +46.7% | +49.6% | +27.9% | +7.4% | +6.9% | +11.0% | +7.4% | +12.9% |
| Operating profit growth | +46.4% | +42.0% | +70.3% | +10.8% | +8.7% | +12.8% | +7.9% | +6.9% |
| Net profit growth | -21.3% | -13.9% | +27.5% | +38.9% | +39.6% | +25.3% | +173.5% | +14.4% |
| EPS growth | -25.8% | -18.5% | +32.0% | +41.5% | +31.1% | +19.0% | +195.1% | +18.7% |
| OPM % | 36.0% | 34.0% | 36.0% | 36.0% | 36.0% | 35.0% | 36.0% | 34.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Eris Lifesciences reported sales of ₹3,129.00 crore (+8.1%) and net profit of ₹648.00 crore (+72.8%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 3,129 | 1,120 | 36.00 | 648.00 | 44.72 |
| Mar 2025 | 2,894 | 1,018 | 35.00 | 375.00 | 25.84 |
| Mar 2024 | 2,009 | 677.00 | 34.00 | 397.00 | 28.82 |
| Mar 2023 | 1,685 | 539.00 | 32.00 | 374.00 | 28.10 |
| Mar 2022 | 1,347 | 489.00 | 36.00 | 406.00 | 29.88 |
| Mar 2021 | 1,212 | 431.00 | 36.00 | 355.00 | 26.16 |
| Mar 2020 | 1,074 | 372.00 | 35.00 | 297.00 | 21.84 |
| Mar 2019 | 982.00 | 345.00 | 35.00 | 291.00 | 21.15 |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +14.7% | +9.4% | +12.8% | +11.1% | +25.1% | +19.2% | +44.1% | +8.1% |
| Operating profit growth | +7.1% | +7.8% | +15.9% | +13.5% | +10.2% | +25.6% | +50.4% | +10.0% |
| Net profit growth | -1.4% | +2.1% | +19.5% | +14.4% | -7.9% | +6.1% | -5.5% | +72.8% |
| EPS growth | -1.1% | +3.3% | +19.8% | +14.2% | -6.0% | +2.6% | -10.3% | +73.1% |
| OPM % | 35.0% | 35.0% | 36.0% | 36.0% | 32.0% | 34.0% | 35.0% | 36.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Eris Lifesciences.
Get Free AI Stock Analysis FREE →Latest News
-
GLP-1 market to grow four-fold to Rs 15,700 crore by FY32; Sun Pharma, Eris, Torrent among likely gainers
-
Eris Lifesciences schedules analyst meet with HBM Partners on August 27 - scanx.trade
-
Torrent Pharma, Eris Lifesciences: भारतीय कंपन्यांचा जेनेरिक GLP-1 मार्केटमध्ये दबदबा - Whalesbook
-
Torrent Pharma, Eris Lifesciences: भारतीय कंपन्यांचा जेनेरिक GLP-1 मार्केटमध्ये दबदबा - Whalesbook
-
Torrent Pharma, Eris Lifesciences: भारतीय कंपन्यांचा जेनेरिक GLP-1 मार्केटमध्ये दबदबा - Whalesbook
-
Torrent Pharma, Eris Lifesciences: भारतीय कंपन्यांचा जेनेरिक GLP-1 मार्केटमध्ये दबदबा - Whalesbook
-
Torrent Pharma, Eris Lifesciences: भारतीय कंपन्यांचा जेनेरिक GLP-1 मार्केटमध्ये दबदबा - Whalesbook
-
Torrent Pharma, Eris Lifesciences: भारतीय कंपन्यांचा जेनेरिक GLP-1 मार्केटमध्ये दबदबा - Whalesbook
-
Torrent Pharma, Eris Lifesciences: भारतीय कंपन्यांचा जेनेरिक GLP-1 मार्केटमध्ये दबदबा - Whalesbook
-
Eris Lifesciences Faces Margin Pressure Following Swiss Parenterals Remediation - whalesbook.com
Frequently Asked Questions
What is Eris Lifesciences's current stock price?
Eris Lifesciences shares were last quoted at ₹1,154.10 (-1.4% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Eris Lifesciences?
Eris Lifesciences has a price-to-earnings (P/E) ratio of 27.16 and a price-to-book (P/B) ratio of 4.32. The industry P/E is 53.33.
What is the 52-week high and low of Eris Lifesciences?
The 52-week high of Eris Lifesciences is ₹1,737.00 and the 52-week low is ₹1,237.90.
What is the market cap of Eris Lifesciences?
The market capitalisation of Eris Lifesciences is about ₹17,490.08 crore.
How did Eris Lifesciences perform in its latest quarterly results?
In the latest quarter (Jun 2026), Eris Lifesciences reported sales of ₹873.00 crore (+12.9%) and net profit of ₹143.00 crore (+14.4%), compared with the same quarter last year.
Is Eris Lifesciences a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Eris Lifesciences has a 3-year ROE of 16.00%, 3-year profit growth of 19.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Eris Lifesciences?
Promoters hold about 54.14% of Eris Lifesciences.
Which sector does Eris Lifesciences belong to?
Eris Lifesciences belongs to the Pharmaceuticals & Drugs sector.